Spera Pharma to Speak at AndTech Seminar: Basics, Applications, Formulation Design, Manufacturing Processes, and Analytical/Quality Evaluation Technology for Lipid Nanoparticles

Hideaki Yamada of the Development and Analytical Research Institute at the Osaka Research Center of Spera Pharma, Inc. (Headquarters: Osaka, Japan; President: Keitaro Iwaki) will serve as a lecturer at the seminar hosted by AndTech, Inc. on Thursday, May 28, 2026, titled 'Basics, Applications, Formulation Design, Manufacturing Processes, and Analytical and Quality Evaluation Technology for Lipid Nanoparticles to Promote the Efficacy of Drug Delivery Systems for Nucleic Acids.'

Seminar Overview

Seminar Title: Basics, Applications, Formulation Design, Manufacturing Processes, and Analytical and Quality Evaluation Technology for Lipid Nanoparticles to Promote the Efficacy of Drug Delivery Systems for Nucleic Acids
Date and Time: Thursday, May 28, 2026, 10:30–16:05
Format: Online (Live streaming)
Organizer: AndTech, Inc.
Details: https://andtech.co.jp/seminars/1f1137be-ba3e-68b0-8d12-064fb9a95405

Lecture Content

[Lecture 4] Practical Aspects of Analysis and Quality Evaluation in LNP Formulations (15:05–16:05)

Lecturer:
Hideaki Yamada
Associate Director, Development and Analytical Research Institute, Osaka Research Center, Spera Pharma, Inc.
PhD (Pharmaceutical Sciences)

Key Points of the Lecture:
LNPs are being actively researched and developed as an effective DDS for new drug modalities, represented by mRNA. However, during the development process, it is important that the quality and functional evaluation of the formulation, in addition to the active ingredients contained within, are conducted appropriately. This lecture will introduce the overview and key considerations for quality evaluation methods of LNP formulations, based on analytical technologies for biopharmaceuticals and mid-molecule drugs, which form the foundation of quality evaluation technologies required for LNP formulations, while incorporating practical analytical examples.

Program:
- Introduction to pharmaceutical development and analytical services provided by Spera Pharma and Astena Holdings
- Quality control and background of LNP
2.1 Diversifying drug discovery modalities and required analytical methods
2.2 Key considerations in quality evaluation of DDS formulations
2.3 Quality control of Lipid Nanoparticles (LNP)
- Specific discussions on analytical methods for quality evaluation of LNP
3.1 Activity testing
3.2 Capillary electrophoresis
3.3 Charge variant analysis
3.4 Aggregate management
3.5 Management and challenges of impurities in nucleic acids, etc.
3.6 Evaluation methods used for mRNA quality control
3.7 Evaluation methods used for LNP quality control
- Q&A

Registration:
Please apply via the button below (Capacity: 30 people).